Low weight-adjusted muscle mass (ASM/BMI) was significantly associated with the frequent exacerbation phenotype in COPD, with the strongest association observed in patients with a BMI < 24 kg/m², while the traditional height-adjusted measure (ASMI) showed no significant association.
Low ASMI (height-adjusted muscle mass index) was not significantly associated with the frequent exacerbation phenotype in COPD patients.
Low ASM/BMI (appendicular skeletal muscle mass-to-body mass index ratio) was significantly associated with the frequent exacerbation phenotype in COPD patients.
The association between low ASM/BMI and the frequent exacerbation phenotype was significantly modified by BMI category.
Among patients with a BMI < 24 kg/m², low ASM/BMI had the strongest association with the frequent exacerbation phenotype.
Among patients with a BMI ≥ 24 kg/m², there was no observed association between low ASM/BMI and the frequent exacerbation phenotype.
The study authors concluded that muscle mass in COPD should be interpreted in the context of body weight rather than height alone.
This research suggests that the way doctors measure muscle mass in patients with COPD (a serious lung disease) matters significantly. Traditionally, muscle mass is compared to a person's height to get a standardized score. However, this study of 419 COPD patients found that this height-based measure was not meaningfully linked to whether patients had frequent dangerous flare-ups of their disease. In contrast, a newer measure that compares muscle mass to body weight (expressed as BMI) did show a significant connection to frequent flare-ups. The connection between the weight-adjusted muscle measure and frequent flare-ups was especially strong in patients with a lower body weight (BMI below 24 kg/m²). In this group, patients with low muscle mass relative to their body weight were over five times more likely to experience frequent exacerbations. However, in patients with a higher BMI (24 kg/m² or above), no such link was found. This suggests that the weight-adjusted muscle measure may be particularly informative for leaner or underweight COPD patients, where the traditional height-based measure may be misleading because significant weight loss can artificially make muscle levels appear more depleted than they functionally are. This research suggests that clinicians managing COPD patients — especially those who are lean or losing weight — might benefit from considering muscle mass in relation to body weight as an additional piece of information, rather than relying solely on height-adjusted measures. The authors caution that ASM/BMI should not be used alone to guide clinical decisions but rather as a complementary tool, and they call for further studies to confirm these findings.
Upload your bloodwork. We'll cross-reference your results against this study and 4,700 others.
Upload Your LabsZhang Y, Xu C, Jiang X, Qu L, Chen Z, Cheng Q, et al.. (2026). Association of Low Weight-Adjusted Muscle Mass with the Frequent Exacerbation Phenotype in COPD: A Retrospective Cross-Sectional Study.. International journal of chronic obstructive pulmonary disease. https://doi.org/10.2147/COPD.S633358